Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

MLA

Tapper, E. B., et al. “Real-World Effectiveness for 12 Weeks of Ledipasvir-Sofosbuvir for Genotype 1 Hepatitis C: The Trio Health Study.” Journal of Viral Hepatitis, vol. 24, no. 1, Jan. 2017, pp. 22–27. EBSCOhost, https://doi.org/10.1111/jvh.12611.

APA

Tapper, E. B., Bacon, B. R., Curry, M. P., Dieterich, D. T., Flamm, S. L., Guest, L. E., Kowdley, K. V., Lee, Y., Tsai, N. C., Younossi, Z. M., & Afdhal, N. H. (2017). Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. Journal of Viral Hepatitis, 24(1), 22–27. https://doi.org/10.1111/jvh.12611

Chicago

Tapper, E B, B R Bacon, M P Curry, D T Dieterich, S L Flamm, L E Guest, K V Kowdley, et al. 2017. “Real-World Effectiveness for 12 Weeks of Ledipasvir-Sofosbuvir for Genotype 1 Hepatitis C: The Trio Health Study.” Journal of Viral Hepatitis 24 (1): 22–27. doi:10.1111/jvh.12611.